10-K: Stereotaxis Inc. Reports Full Year 2023 Results, Cites Supply Chain and Macroeconomic Headwinds

Stereotaxis, Inc. reports a decrease in revenue for 2023, impacted by supply chain issues and macroeconomic factors, while highlighting growth in system sales.

Summary

• Stereotaxis, Inc. reported a total revenue of $26.8 million for the year ended December 31, 2023, a decrease of approximately 5% compared to $28.1 million in 2022.
• System sales increased by 28% to $8.7 million, while revenue from disposables, service, and accessories decreased by 15% to $18.0 million.
• The company experienced a decrease in gross margin from 66% in 2022 to 56% in 2023, primarily due to changes in product mix.
• Research and development expenses decreased slightly by 3% to $10.3 million.
• The company reported a net loss of $20.7 million for 2023, compared to a net loss of $18.3 million in 2022.
• As of December 31, 2023, the company had a backlog of approximately $14.7 million, with 81% expected to be recognized as revenue in 2024.
• The company's liquidity is largely dependent on clinical adoption of its robotic magnetic navigation system and new system placements.
• The company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations or expense reductions are in place.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with positive growth in system sales but overall revenue decline and increased losses. The company faces significant challenges related to supply chain, macroeconomic conditions, and regulatory approvals. The sentiment is cautiously negative due to the financial losses and operational risks.

Positives

• System sales experienced significant growth, increasing by 28% in 2023.
• The company has a substantial backlog, indicating future revenue potential.
• The company is actively expanding its technology into new clinical areas.
• The company has established strategic relationships to support its commercialization efforts.
• The company is actively pursuing regulatory approvals for new products.

Negatives

• Total revenue decreased by approximately 5% in 2023.
• Revenue from disposables, service, and accessories decreased by 15% in 2023.
• Gross margin decreased from 66% to 56% in 2023.
• The company experienced a net loss of $20.7 million in 2023.
• The company continues to experience supply chain disruptions and inflationary pressures.

Risks

• The company may not generate cash from operations or be able to raise the necessary capital to continue operations.
• Macroeconomic and geopolitical factors, as well as pandemics, epidemics or outbreaks of infectious disease could have an adverse effect our supply chain, our hospital customer buying patterns, and our ability to raise capital and could otherwise disrupt our normal business operations.
• Hospital decision-makers may not purchase the company's robotic magnetic navigation systems or related products.
• The company may not be able to fulfill current purchase orders and other commitments on a timely basis.
• The company will likely experience long and variable sales and installation cycles.
• Physicians may not use the company's products if they do not believe they are safe, efficient and effective.
• The company's collaborations with fluoroscopy system manufacturers and providers of catheters and electrophysiology mapping systems may fail.
• The company relies on contract manufacturers and on suppliers, and in some cases, a single supplier, which could harm the ability to meet demand for products.
• The company may be unable to protect its technology from use by third parties.
• The company may fail to comply with continuing regulatory requirements of the FDA and other authorities.
• Hospitals or physicians may be unable to obtain reimbursement from third-party payors for procedures using the company's products.

Future Outlook

The company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations or expense reductions are in place. The company's liquidity needs will be largely determined by the success of clinical adoption within the installed base of its robotic magnetic navigation system as well as by new placements of capital systems.

Management Comments

• The company has shared its aspiration and a product strategy to expand the clinical focus of its technology to several additional endovascular indications including coronary, neuro, and peripheral interventions.
• The company believes that its robotic technology can enhance procedure results by improving navigation of disposable interventional devices to treatment sites, and by affecting more precise and safe treatments once these sites are reached.
• The company believes that its robotic technology can allow procedures that previously required the highest levels of manual dexterity and skill to be performed effectively by a broader range of interventional physicians, with more standardized outcomes.

Industry Context

The company operates in the competitive medical device market, particularly in electrophysiology, where it faces competition from traditional catheter-based approaches and companies developing new technologies. The company's focus on robotic magnetic navigation and its expansion into new clinical areas positions it to address the challenges in interventional procedures.

Comparison to Industry Standards

• The company's revenue growth is below the industry average for medical device companies, which is estimated to be around 10% annually.
• The company's gross margin of 56% is lower than the industry average for medical device companies, which is typically between 60% and 70%.
• The company's net loss indicates that it is not yet profitable, which is not uncommon for companies in the early stages of commercialization.
• The company's backlog of $14.7 million is a positive sign, but it is important to note that some of these orders are subject to contingencies.
• The company's reliance on strategic relationships is a common practice in the medical device industry, but it also introduces risks related to the performance of these partners.

Legal Proceedings

• The Company is involved from time to time in various lawsuits and claims arising in the normal course of business. Although the outcomes of these lawsuits and claims are uncertain, the Company does not believe any of them are likely to have a material adverse effect on our business, financial condition or results of operations.

Stakeholder Impact

• Shareholders may experience dilution due to potential future issuances of securities.
• Employees may be affected by the company's financial performance and potential cost-cutting measures.
• Customers may experience delays in product delivery and installation due to supply chain issues.
• Suppliers may be affected by the company's financial performance and potential changes in purchasing patterns.
• Creditors may be affected by the company's financial performance and ability to repay debts.

Next Steps

• The company will focus on improving the operating performance of the company.
• The company will focus on raising additional funds through debt or equity financing.
• The company will continue to pursue regulatory approvals for the Stereotaxis MAGiC catheter.
• The company will continue to manage supply chain disruptions and inflationary pressures.

Key Dates

Keywords

Robotic Magnetic Navigation, Electrophysiology, Cardiac Ablation, Interventional Laboratory, Genesis RMN System, Odyssey Solution, Disposable Devices, Regulatory Approvals, Supply Chain, Healthcare Technology